Table 3.
Characterization of the Relationship between Clinicopathologic Factors and Adiposity Variables
| BMI | VFA/SFA ratio | PNF, mm | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mean | SD | p Value |
<30 (n = 57) |
≥30 (n = 39) |
p Value |
Mean | SD | p Value |
V/S <0.4 (n = 38) |
V/S ≥0.4 (n = 61) |
p Value |
Mean | SD | p Value |
|
| Age, y (mean) | 63 (13.2) | 57 (11.4) | 0.03 | 56.1 (14.5) | 63.4 (11.2) | 0.006 | |||||||||
| Sex | |||||||||||||||
| Male | 29.7 | 5.6 | 0.13 | 29 (51.8) | 25 (64.1) | 0.29 | 0.67 | 0.32 | <0.001 | 10 (26.3) | 47 (77.1) | <0.001 | 18.0 | 9.0 | <0.001 |
| Female | 27.6 | 7.6 | 27 (48.2) | 14 (35.9) | 0.37 | 0.18 | 28 (73.7) | 14 (22.9) | 7.1 | 6.3 | |||||
| Comorbidities | |||||||||||||||
| Hypertension | 30.0 | 6.8 | 0.13 | 20 (35.7) | 19 (48.7) | 0.29 | 0.66 | 0.31 | 0.002 | 10 (26.3) | 30 (50) | 0.02 | 16.2 | 8.6 | 0.01 |
| None | 27.9 | 6.4 | 36 (67.3) | 20 (51.3) | 0.47 | 0.28 | 28 (73.7) | 30 (50) | 11.2 | 9.7 | |||||
| Dyslipidemia | 28.8 | 7.3 | 0.99 | 10 (17.9) | 8 (20.5) | 0.79 | 0.67 | 0.36 | 0.05 | 3 (7.9) | 16 (26.7) | 0.03 | 16.6 | 12.3 | 0.08 |
| None | 28.8 | 6.5 | 46 (82.1) | 31 (79.5) | 0.51 | 0.29 | 35 (92.1) | 44 (73.3) | 12.4 | 8.7 | |||||
| Diabetes | 32.0 | 7.9 | 0.03 | 8 (14.0) | 8 (20.5) | 0.58 | 0.66 | 0.38 | 0.09 | 3 (7.9) | 13 (21.7) | 0.09 | 19.1 | 12.2 | 0.04 |
| None | 28.1 | 6.1 | 48 (85.7) | 31 (79.5) | 0.52 | 0.29 | 35 (92.1) | 47 (78.3) | 12.1 | 8.6 | |||||
| Preoperative stage | |||||||||||||||
| Stage II | 28.8 | 6.3 | 0.62 | 23 (46.9) | 14 (38.9) | 0.51 | 0.59 | 0.29 | 0.31 | 12 (35.3) | 26 (48.2) | 0.27 | 13.6 | 7.7 | 0.85 |
| Stage III | 29.5 | 6.9 | 26 (53.1) | 22 (61.1) | 0.52 | 0.33 | 22 (64.7) | 28 (51.9) | 14.0 | 11.1 | |||||
| Pathologic response to neoadjuvant treatment | |||||||||||||||
| None/partial | 28.4 | 6.7 | 0.29 | 47 (84.0) | 24 (61.5) | 0.02 | 0.56 | 0.31 | 0.52 | 26 (68.4) | 48 (78.7) | 0.34 | 13.0 | 9.5 | 0.56 |
| Complete | 30.3 | 6.2 | 9 (16.0) | 15 (38.5) | 0.51 | 0.32 | 12 (32.6) | 13 (21.3) | 14.3 | 10.0 | |||||
| Histologic grade after neoadjuvant | |||||||||||||||
| Well/moderate* | 28.9 | 6.6 | 0.42 | 51 (96.2) | 35 (89.7) | 0.40 | 0.55 | 0.31 | 0.26 | 35 (94.6) | 55 (93.2) | 1.0 | 13.2 | 9.7 | 0.46 |
| Poorly/undifferentiated | 31.1 | 6.0 | 2 (3.8) | 4 (10.3) | 0.40 | 0.17 | 2 (5.4) | 4 (6.8) | 16.2 | 9.1 | |||||
| Surgical site infection | |||||||||||||||
| No | 28.1 | 6.2 | 0.06 | 48 (85.7) | 28 (71.8) | 0.10 | 0.55 | 0.30 | 0.86 | 29 (78.4) | 50 (82.0) | 0.66 | 12.6 | 8.5 | 0.18 |
| Yes | 31.3 | 7.7 | 8 (14.3) | 11 (28.2) | 0.54 | 0.36 | 8 (21.6) | 11 (18.0) | 16.9 | 13.1 | |||||
| Postoperative complication | |||||||||||||||
| No | 29.3 | 6.5 | 0.43 | 29 (51.8) | 24 (61.5) | 0.35 | 0.56 | 0.31 | 0.74 | 22 (59.5) | 34 (55.7) | 0.72 | 14.0 | 8.8 | 0.50 |
| Yes | 28.2 | 6.7 | 27 (48.2) | 15 (38.5) | 0.54 | 0.31 | 15 (40.5) | 27 (44.3) | 12.7 | 10.7 | |||||
Adiposity variables, BMI, V/S, and PNF. Differences in adiposity by factors determined by one-way ANOVA or chi-square Fisher’s exact test.
*
Well to moderate category includes 2 patients that had complete response to neoadjuvant treatment and no tumor remaining at surgery.
BMI, body mass index; PNF, perinephric fat thickness; SFA, subcutaneous fat area; VFA, visceral fat area; V/S, visceral fat to subcutaneous fat ratio.